VIDEO: Ubrogepant prevents headache when administered in prodromal phase
Click Here to Manage Email Alerts
Treatment with 100 mg of ubrogepant in the prodromal phase prevented development of headaches as soon as 24 hours post-dose compared with placebo, according to study co-author Peter J. Goadsby, MD, PhD, FRS.
“Importantly, 75% of participants reported some functional disability,” Goadsby, professor of neurology at Kings College, London, said in this Healio video. “With ubrogepant, compared to placebo, this had improved by 2 hours, and that was maintained out to 80 hours.”
Goadsby and colleagues conducted a phase 3 randomized, double-blind, placebo-controlled crossover study that examined safety and efficacy of 100 mg ubrogepant administered during the premonitory phase of a migraine attack to 480 individuals.
The study results were presented at the European Headache Federation.
Researchers found reduction of moderate-to-severe intensity headache within 24 hours was achieved following 45.5% of ubrogepant-treated qualifying prodrome events vs. 28.6% of placebo-treated events, and absence of headache of any intensity within 24 hours was significant with ubrogepant compared to placebo (23.7% vs 13.9%).